Safety of <sup>90</sup>Y-ibritumomab Tiuxetan Treatment for Japanese Patients in Real-world Clinical Practice
نویسندگان
چکیده
منابع مشابه
Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan.
Radioimmunotherapy is a new cancer therapy that combines the cytotoxicity of radiation with the tumor-specific targeting of monoclonal antibodies. Yttrium 90 (Y-90) ibritumomab tiuxetan (Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), includ...
متن کاملLong‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice
The Icatibant Outcome Survey (IOS) is an observational study monitoring safety and effectiveness of icatibant in the real-world setting. We analyzed safety data from 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009 and February 2015). Icatibant was generally well tolerated. Excluding off-label use and pregnancy, 438 patients (78.6%) did not report adverse events (AEs)....
متن کاملComparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
UNLABELLED We retrospectively evaluated our single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL). We evaluated the hypothesis that the patient-specific dosing regimen used with (131)I-tositumomab results in less bone marrow toxicity than does the weight-based dosing regimen used with (90)Y-ibritumomab tiu...
متن کاملRadiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).
Radioimmunotherapy is a recently approved treatment modality for non-Hodgkin's lymphoma that enables physicians to target cytotoxic localized radiation to tumor sites without using external-beam sources. Because it uses a pure beta emitter for therapy, (90)Y ibritumomab tiuxetan can be safely and routinely administered in an outpatient procedure, with few discharge instructions, and minimal ris...
متن کاملRadioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
The increasing incidence of non-Hodgkin's lymphoma (NHL), coupled with the lack of optimal treatment options, has prompted the development of novel treatments. Of these, radioimmunotherapy is one of the most promising. Two of the radiolabeled monoclonal antibody therapies being studied in the treatment of NHL are yttrium 90 (90Y) ibritumomab tiuxetan and iodine 131 (131I) tositumomab. The radio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: YAKUGAKU ZASSHI
سال: 2019
ISSN: 0031-6903,1347-5231
DOI: 10.1248/yakushi.18-00112